Literature DB >> 17632695

[Treatment of atrial fibrillation].

P Kirchhof1, G Breithardt.   

Abstract

Atrial fibrillation is a common and in most patients recurrent arrhythmia. Atrial fibrillation can increase mortality and causes at times severe symptoms in affected patients. Timely initiation of sustained oral anticoagulation is indicated in patients with atrial fibrillation at risk for stroke to prevent thromboembolic complications. Patients at risk for stroke can be identified by clinical characteristics using validated score systems, e.g., the CHADS(2) score or the Framingham score. Drugs that slow AV nodal conduction can improve symptoms associated with high ventricular rate. Cardioversion can acutely terminate atrial fibrillation in almost all patients, but many patients suffer from recurrent atrial fibrillation. The prevention of arrhythmia recurrences ("rhythm control therapy") is indicated in patients with severe arrhythmia-related symptoms. Antiarrhythmic drugs can approximately double the maintenance rate of sinus rhythm. Other drugs that were not primarily developed as antiarrhythmic agents, e.g., ACE inhibitors, sartans, and possibly statins, can further improve maintenance of sinus rhythm in selected patient groups. Catheter-based isolation of the pulmonary veins is a recently developed intervention that can cure some forms of atrial fibrillation. It is likely that a multimodal therapeutic approach will in the future allow rhythm control therapy to become more effective.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17632695     DOI: 10.1007/s00108-007-1899-5

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  23 in total

1.  A trial of self-adhesive patch electrodes and hand-held paddle electrodes for external cardioversion of atrial fibrillation (MOBIPAPA).

Authors:  Paulus Kirchhof; Gerold Mönnig; Kristina Wasmer; Achim Heinecke; Günter Breithardt; Lars Eckardt; Dirk Böcker
Journal:  Eur Heart J       Date:  2005-02-25       Impact factor: 29.983

2.  ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society.

Authors:  Valentin Fuster; Lars E Rydén; David S Cannom; Harry J Crijns; Anne B Curtis; Kenneth A Ellenbogen; Jonathan L Halperin; Jean-Yves Le Heuzey; G Neal Kay; James E Lowe; S Bertil Olsson; Eric N Prystowsky; Juan Luis Tamargo; Samuel Wann; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Jeffery L Anderson; Elliott M Antman; Jonathan L Halperin; Sharon Ann Hunt; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel; Silvia G Priori; Jean-Jacques Blanc; Andrzej Budaj; A John Camm; Veronica Dean; Jaap W Deckers; Catherine Despres; Kenneth Dickstein; John Lekakis; Keith McGregor; Marco Metra; Joao Morais; Ady Osterspey; Juan Luis Tamargo; José Luis Zamorano
Journal:  Europace       Date:  2006-09       Impact factor: 5.214

3.  Targeted pharmacological reversal of electrical remodeling after cardioversion--rationale and design of the Flecainide Short-Long (Flec-SL) trial.

Authors:  Paulus Kirchhof; Thomas Fetsch; Peter Hanrath; Thomas Meinertz; Gerhard Steinbeck; Walter Lehmacher; Günter Breithardt
Journal:  Am Heart J       Date:  2005-11       Impact factor: 4.749

Review 4.  Rate-control vs. rhythm-control in patients with atrial fibrillation: a meta-analysis.

Authors:  Luca Testa; Giuseppe G L Biondi-Zoccai; Antonio Dello Russo; Fulvio Bellocci; Felicita Andreotti; Filippo Crea
Journal:  Eur Heart J       Date:  2005-05-04       Impact factor: 29.983

Review 5.  Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials.

Authors:  Gregory W Albers
Journal:  Am J Manag Care       Date:  2004-12       Impact factor: 2.229

6.  Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach.

Authors:  Paolo Alboni; Giovanni L Botto; Nicola Baldi; Mario Luzi; Vitantonio Russo; Lorella Gianfranchi; Paola Marchi; Massimo Calzolari; Alberto Solano; Raffaele Baroffio; Germano Gaggioli
Journal:  N Engl J Med       Date:  2004-12-02       Impact factor: 91.245

7.  Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.

Authors:  Scott D Corley; Andrew E Epstein; John P DiMarco; Michael J Domanski; Nancy Geller; H Leon Greene; Richard A Josephson; Joyce C Kellen; Richard C Klein; Andrew D Krahn; Mary Mickel; L Brent Mitchell; Joy Dalquist Nelson; Yves Rosenberg; Eleanor Schron; Lynn Shemanski; Albert L Waldo; D George Wyse
Journal:  Circulation       Date:  2004-03-08       Impact factor: 29.690

8.  Cardiac surgery for arrhythmias.

Authors:  James L Cox
Journal:  Pacing Clin Electrophysiol       Date:  2004-02       Impact factor: 1.976

9.  Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study.

Authors:  Jan Heeringa; Deirdre A M van der Kuip; Albert Hofman; Jan A Kors; Gerard van Herpen; Bruno H Ch Stricker; Theo Stijnen; Gregory Y H Lip; Jacqueline C M Witteman
Journal:  Eur Heart J       Date:  2006-03-09       Impact factor: 29.983

10.  Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats.

Authors:  M C Wijffels; C J Kirchhof; R Dorland; M A Allessie
Journal:  Circulation       Date:  1995-10-01       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.